A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody

X Yang; P Macarthur

doi:10.1111/avj.70088

May 5, 2026Australian Veterinary JournalOpen Access

A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody

View Full Paper

Ask AI

Bookmark

Share

Key Points

To appraise the safety of bedinvetmab compared to traditional treatments in dogs with osteoarthritis.
Literature search identified four relevant articles on bedinvetmab's safety.
Studies compared adverse events associated with bedinvetmab to controls and meloxicam.
Disproportionality analysis was conducted to assess AE reporting rates.
No increase in adverse events was observed with bedinvetmab versus placebo in two studies.
Bedinvetmab had fewer adverse events compared to meloxicam in another study.
Musculoskeletal adverse events were reported more frequently for bedinvetmab than traditional therapies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Critical appraisal demonstrates mixed evidence on safety of bedinvetmab in dogs with osteoarthritis, suggesting monitoring for adverse events is necessary.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69fbefa3164b5133a91a3933 https://doi.org/10.1111/avj.70088

View Full Paper

Ask AI

Bookmark

Share

A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody

Key Points

No abstract yet

Implication

Discussion

Cite This Study

A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading